[go: up one dir, main page]

MX2013005645A - Suministro local vascular de una combinacion de un agonista del receptor de adenosina a2a / inhibidor de la fosfodiesterasa para reducir la lesion del miocardio. - Google Patents

Suministro local vascular de una combinacion de un agonista del receptor de adenosina a2a / inhibidor de la fosfodiesterasa para reducir la lesion del miocardio.

Info

Publication number
MX2013005645A
MX2013005645A MX2013005645A MX2013005645A MX2013005645A MX 2013005645 A MX2013005645 A MX 2013005645A MX 2013005645 A MX2013005645 A MX 2013005645A MX 2013005645 A MX2013005645 A MX 2013005645A MX 2013005645 A MX2013005645 A MX 2013005645A
Authority
MX
Mexico
Prior art keywords
receptor agonist
stent
myocardial injury
adenosine receptor
adenosine
Prior art date
Application number
MX2013005645A
Other languages
English (en)
Other versions
MX361633B (es
Inventor
Robert Falotico
Jonathon Z Zhao
Theodore L Parker
Andrew Luk
Original Assignee
Cordis Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cordis Corp filed Critical Cordis Corp
Publication of MX2013005645A publication Critical patent/MX2013005645A/es
Publication of MX361633B publication Critical patent/MX361633B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L31/00—Materials for other surgical articles, e.g. stents, stent-grafts, shunts, surgical drapes, guide wires, materials for adhesion prevention, occluding devices, surgical gloves, tissue fixation devices
    • A61L31/02—Inorganic materials
    • A61L31/022—Metals or alloys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L31/00—Materials for other surgical articles, e.g. stents, stent-grafts, shunts, surgical drapes, guide wires, materials for adhesion prevention, occluding devices, surgical gloves, tissue fixation devices
    • A61L31/04—Macromolecular materials
    • A61L31/06—Macromolecular materials obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L31/00—Materials for other surgical articles, e.g. stents, stent-grafts, shunts, surgical drapes, guide wires, materials for adhesion prevention, occluding devices, surgical gloves, tissue fixation devices
    • A61L31/08—Materials for coatings
    • A61L31/10—Macromolecular materials
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L31/00—Materials for other surgical articles, e.g. stents, stent-grafts, shunts, surgical drapes, guide wires, materials for adhesion prevention, occluding devices, surgical gloves, tissue fixation devices
    • A61L31/14—Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
    • A61L31/16—Biologically active materials, e.g. therapeutic substances
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
    • A61L2300/40—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a specific therapeutic activity or mode of action
    • A61L2300/416—Anti-neoplastic or anti-proliferative or anti-restenosis or anti-angiogenic agents, e.g. paclitaxel, sirolimus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
    • A61L2300/40—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a specific therapeutic activity or mode of action
    • A61L2300/432—Inhibitors, antagonists
    • A61L2300/434—Inhibitors, antagonists of enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
    • A61L2300/40—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a specific therapeutic activity or mode of action
    • A61L2300/432—Inhibitors, antagonists
    • A61L2300/436—Inhibitors, antagonists of receptors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
    • A61L2300/60—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a special physical form
    • A61L2300/606—Coatings
    • A61L2300/608—Coatings having two or more layers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
    • A61L2300/60—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a special physical form
    • A61L2300/606—Coatings
    • A61L2300/608—Coatings having two or more layers
    • A61L2300/61—Coatings having two or more layers containing two or more active agents in different layers

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Vascular Medicine (AREA)
  • Epidemiology (AREA)
  • Surgery (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Inorganic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Molecular Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Media Introduction/Drainage Providing Device (AREA)
  • Materials For Medical Uses (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)

Abstract

Una endoprótesis u otro dispositivo médico implantable pueden emplearse para el suministro local de un agonista selectivo del receptor de adenosina en combinación con otros agentes terapéuticos para reducir la lesión miocárdica después de un infarto agudo del miocardio; tan pronto como sea posible después de un infarto agudo del miocardio se coloca una endoprótesis u otro dispositivo adecuado que comprende y es capaz de suministrar un agonista selectivo del receptor de adenosina en el vaso sanguíneo con la oclusión responsable de causar el infarto; una vez en posición, la endoprótesis u otro dispositivo intraluminal se despliega para eliminar la oclusión y restablecer el flujo sanguíneo al área, región o volumen de tejido específico del corazón; durante un período de tiempo dado el agonista selectivo del receptor de adenosina solo o en combinación con otros agentes terapéuticos eluye de la endoprótesis u otro dispositivo hacia el flujo sanguíneo coronario corriente abajo en el tejido cardíaco hipóxico durante un tiempo suficiente para reducir el nivel de daño al miocardio.
MX2013005645A 2010-11-18 2011-11-09 Suministro local vascular de una combinacion de un agonista del receptor de adenosina a2a / inhibidor de la fosfodiesterasa para reducir la lesion del miocardio. MX361633B (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US41505610P 2010-11-18 2010-11-18
US12/971,083 US20120130481A1 (en) 2010-11-18 2010-12-17 Local vascular delivery of adenosine a2a receptor agonists in combination with other agents to reduce myocardial injury
PCT/US2011/060004 WO2012067913A1 (en) 2010-11-18 2011-11-09 Local vascular delivery of an adenosine a2a receptor agonist / phosphodiesterase inhibitor combination to reduce myocardial injury

Publications (2)

Publication Number Publication Date
MX2013005645A true MX2013005645A (es) 2013-07-03
MX361633B MX361633B (es) 2018-12-13

Family

ID=46065055

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2013005645A MX361633B (es) 2010-11-18 2011-11-09 Suministro local vascular de una combinacion de un agonista del receptor de adenosina a2a / inhibidor de la fosfodiesterasa para reducir la lesion del miocardio.

Country Status (12)

Country Link
US (1) US20120130481A1 (es)
EP (1) EP2640434A1 (es)
JP (1) JP2014502193A (es)
KR (1) KR20130131373A (es)
CN (1) CN103209720B (es)
AU (1) AU2011329270B2 (es)
BR (1) BR112013011883A2 (es)
CA (1) CA2815388A1 (es)
IL (1) IL225643A0 (es)
MX (1) MX361633B (es)
RU (1) RU2565403C2 (es)
WO (1) WO2012067913A1 (es)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN110711056A (zh) * 2014-10-28 2020-01-21 株式会社Jimro 药物洗脱支架
US11839614B2 (en) 2018-01-31 2023-12-12 Intra-Cellular Therapies, Inc. Methods for treating or mitigating cardiotoxicity characterized by inhibition of adenosine A2 signaling and/or adenosine A2 receptor expression
CN121197403A (zh) * 2019-04-28 2025-12-26 中国医学科学院阜外医院 磷酸二酯酶4抑制剂的用途
EP3998049B1 (en) * 2019-07-09 2024-08-21 Otsuka Medical Devices Co., Ltd. Drug-eluting stent

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ZA737247B (en) 1972-09-29 1975-04-30 Ayerst Mckenna & Harrison Rapamycin and process of preparation
US20030077312A1 (en) * 2001-10-22 2003-04-24 Ascher Schmulewicz Coated intraluminal stents and reduction of restenosis using same
WO2004043510A1 (en) * 2002-11-08 2004-05-27 Conor Medsystems, Inc. Method and apparatus for reducing tissue damage after ischemic injury
US20070269486A1 (en) * 2005-03-14 2007-11-22 Conor Medsystems, Llc. Methods and Devices for Reducing Tissue Damage After Ischemic Injury
EP1834636A1 (en) * 2006-03-08 2007-09-19 Sahajanand Medical Technologies PVT. ltd Compositions comprising porous articles and uses in implantable medical devices
WO2007134271A2 (en) * 2006-05-15 2007-11-22 Innovational Holdings Llc Method and apparatus for reducing injury from acute myocardial infarction
US20080243241A1 (en) * 2007-03-28 2008-10-02 Zhao Jonathon Z Short term sustained drug-delivery system for implantable medical devices and method of making the same
CA2689054C (en) * 2007-05-31 2016-07-12 Adenopaint, Llc Anti-no-reflow guide wire for vascular interventional procedures
US8883500B2 (en) * 2008-12-05 2014-11-11 Northeastern University Method of preparing adenosine-resistant anti-tumor T lymphocytes for adoptive immunotherapy
US20100161039A1 (en) * 2008-12-23 2010-06-24 Vipul Dave Adhesion promoting temporary mask for coated surfaces
AU2010200316A1 (en) * 2009-01-30 2010-08-19 Cordis Corporation Reservoir Eluting Stent
US20100280600A1 (en) * 2009-04-30 2010-11-04 Vipul Bhupendra Dave Dual drug stent

Also Published As

Publication number Publication date
CA2815388A1 (en) 2012-05-24
BR112013011883A2 (pt) 2020-08-04
MX361633B (es) 2018-12-13
RU2565403C2 (ru) 2015-10-20
WO2012067913A8 (en) 2013-06-13
WO2012067913A1 (en) 2012-05-24
RU2013127580A (ru) 2014-12-27
KR20130131373A (ko) 2013-12-03
AU2011329270B2 (en) 2015-03-19
IL225643A0 (en) 2013-06-27
EP2640434A1 (en) 2013-09-25
CN103209720A (zh) 2013-07-17
JP2014502193A (ja) 2014-01-30
CN103209720B (zh) 2016-07-06
AU2011329270A1 (en) 2013-05-02
US20120130481A1 (en) 2012-05-24

Similar Documents

Publication Publication Date Title
MX2013005644A (es) Suministro local vascular de agonistas del receptor de adenosina a2a para reducir el daño al miocardio.
WO2011002239A3 (ko) 포유류의 유핵세포에서 유래된 마이크로베시클 및 이의 용도
WO2008108987A3 (en) Medical device with a porous surface for delivery of a therapeutic agent
WO2012099910A3 (en) Ballstent device and methods of use
JP2011520899A5 (es)
NZ601762A (en) Local delivery of water-soluble or water-insoluble therapeutic agents to the surface of body lumens
WO2011089620A3 (en) Method and insertable medical device for delivering one or more pro-healing agents to target site within blood vessel post-deployment of stent
MX336013B (es) Dispositivos, sistemas y metodos de administracion terapeuticos.
MX361633B (es) Suministro local vascular de una combinacion de un agonista del receptor de adenosina a2a / inhibidor de la fosfodiesterasa para reducir la lesion del miocardio.
WO2012135656A3 (en) Intra-luminal access apparatus and methods of using the same
MX2010006650A (es) Materiales y metodos para el tratamiento de proliferacion vascular ocular patologica.
ZA201109415B (en) Re-establishment of blood flow in blocked human arteries by transferring nano-encapsulated drug through medical devices,designed for the same and releasing the nano-encapsulated drug in human artery with body ph
WO2007118131A3 (en) Methods and devices for reducing tissue damage after ischemic injury
WO2011089618A3 (en) Drug-eluting insert able medical device for treating acute myocardial infarction, thrombus containing lesions and saphenous- vein graft lesions
WO2007134271A3 (en) Method and apparatus for reducing injury from acute myocardial infarction
WO2007112025A3 (en) Composite vascular prosthesis
CN104352293A (zh) 一种减少晚期血栓形成的药物洗脱支架
Gagnor et al. Chronic total occlusion treatment as a health insurance: Collateral recruitability and bidirectionality
Refiker Randomized trial of aspirin and clopidogrel versus aspirin alone for the prevention of coronary artery bypass graft occlusion: The Preoperative Aspirin and Postoperative Antiplatelets in Coronary Artery Bypass Grafting surgery
CN203885672U (zh) 冠状动脉急诊治疗用双联药物洗脱支架
Talati Hypotension: 2 case reports
Serebruany et al. We-P11: 212 Platelet inhibition with prasugrel (CS-747) versus clopidogrel in patients undergoing coronary stenting (Jumbo platelet substudy)
Li et al. We-P11: 217 Effect on rat vascular smooth muscle cells/monocytes adhesion by stromal cell derived-factor 1 alpha
Burazor et al. We-P11: 214 Clopidogrel in therapy of patients with ACS without ST segment elevation. Our first experience
Wgsäter et al. We-P11: 216 CD137 and CD137 ligand in vascular smooth muscle cells

Legal Events

Date Code Title Description
FG Grant or registration